Skip to content

The Cognitive and Cardiovascular Health in the Elderly Study

The Cognitive and Cardiovascular Health in the Elderly Study

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01979432
Acronym
COACHES
Enrollment
17
Registered
2013-11-08
Start date
2013-12-31
Completion date
2015-12-12
Last updated
2019-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Diseases

Keywords

Alzheimer, cognitive diseases, Ankle-to-brachial index

Brief summary

The main objective of this study is to look for the interest forecast of the IPS as infra-clinical cardiovascular marker in the prediction of a change of the cognitive functions (MCI) at the elderly of 70 and more years old without clinical cardiovascular pathology.

Interventions

Sponsors

University Hospital, Limoges
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Eligibility

Sex/Gender
ALL
Age
70 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* free-living community-dwelling men and women aged ≥ 70 years, * subjects free of clinical CVD related to atherosclerosis * preserved basic activities of daily living (ADL = 6) * without cognitive impairment (MMSE≥24)

Exclusion criteria

* subjects with clinical history of any of the following CVD diseases : coronary artery disease (angina, myocardial infarction, coronary revascularization), cerebrovascular disease (stroke, TIA, carotid revascularization), clinical peripheral artery disease (claudication, critical limb ischemia) * subjects with neurodegenerative, locomotor and ophtalmological diseases unable to perform the cognitive tests * subjects unable to give written informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Incident MCI according to the following criteriaone time point(1) cognitive complaint (self-reported and/or informant) ; (2) preserved basic activities of daily living (ADL) ; (3) cognitive impairment (not normal for age and education) or decline in cognition evidenced by performance on objective cognitive tasks defined as a test performance \<1.0 standard deviations below the mean of the reference group ; (4) preserved general cognitive functioning and (5) absence of dementia.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026